MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Buys 8,931 Shares of Stock

Key Points

• Director Ramiro Guerrero bought 8,931 MAIA shares at an average of $1.39, spending $12,414 and increasing his direct holdings to 610,842 shares. He also reported four additional purchases in August, totaling 147,483 shares across the disclosed transactions.
• MAIA shares fell 0.8% to $1.30 in mid-day trading, remaining below their 50-day and 200-day moving averages. The stock has traded between $0.87 and $3.19 over the past year.
• The clinical-stage biotechnology company reported a quarterly loss of $0.13 per share, missing analyst expectations by $0.02; analysts expect a full-year loss of $0.54 per share.

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Ramiro Guerrero acquired 8,931 shares of the business's stock in a transaction on Wednesday, August 26th. The shares were purchased at an average price of $1.39 per share, for a total transaction of $12,414.09. Following the transaction, the director directly owned 610,842 shares of the company's stock, valued at approximately $849,070.38. The trade was a 1.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero bought 46,620 shares of MAIA Biotechnology stock. The stock was purchased at an average cost of $1.35 per share, for a total transaction of $62,937.00.
• On Thursday, August 27th, Ramiro Guerrero bought 78,239 shares of MAIA Biotechnology stock. The stock was purchased at an average price of $1.39 per share, with a total value of $108,752.21.
• On Monday, August 24th, Ramiro Guerrero purchased 1,794 shares of MAIA Biotechnology stock. The shares were purchased at an average cost of $1.33 per share, with a total value of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero purchased 11,899 shares of MAIA Biotechnology stock. The shares were purchased at an average price of $1.37 per share, for a total transaction of $16,301.63.

MAIA Biotechnology Stock Down 0.8%

NYSEAMERICAN:MAIA traded down $0.01 during mid-day trading on Tuesday, hitting $1.30. 312,335 shares of the stock traded hands, compared to its average volume of 791,682. MAIA Biotechnology, Inc. has a 52 week low of $0.87 and a 52 week high of $3.19. The stock has a market capitalization of $79.08 million, a price-to-earnings ratio of -2.10 and a beta of 0.24. The firm's 50 day moving average is $1.37 and its two-hundred day moving average is $1.44.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, research analysts predict that MAIA Biotechnology, Inc. will post -0.54 EPS for the current year.

Hedge Funds Weigh In On MAIA Biotechnology

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock worth $400,000 after purchasing an additional 7,746 shares during the period. Centric Wealth Management boosted its stake in shares of MAIA Biotechnology by 2.0% during the fourth quarter. Centric Wealth Management now owns 586,398 shares of the company's stock valued at $897,000 after purchasing an additional 11,500 shares during the period. Marshall Wace LLP purchased a new stake in shares of MAIA Biotechnology during the second quarter valued at $29,000. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology in the second quarter worth about $52,000. Finally, PVG Asset Management Corp purchased a new position in MAIA Biotechnology in the 1st quarter worth about $46,000. Hedge funds and other institutional investors own 5.65% of the company's stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source